Pure Global
NCT06094296

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
BMS-986315
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Bristol-Myers Squibb
Location
Boise,Rochester,Charleston,Seattle,Cordoba City,Vina Del Mar,Rome,Gdansk,Cluj-Napoca,Cluj-Napoca,Cluj-napoca,Craiova,Floresti, Argentina,Chile,Italy,Poland,Romania,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Nov 03, 2023
End date
Oct 10, 2027
Enrollment
196 participants
Primary outcome

Part 1: Number of Participants with Adverse Events (AEs),Part 1: Number of Participants with Treatment-related AEs (TRAEs),Part 1: Number of Participants with Serious AEs (SAEs),Part 1: Number of Participants with AEs Meeting Protocol-defined Dose Limiting Toxicity DLT Criteria,Part 1: Number of Participants with AEs Leading to Discontinuation,Part 1: Number of Participants with AEs Leading to Death,Part 2: Objective Response Rate (ORR)

Summary

The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab
 in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in
 combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell
 lung cancer (NSCLC).

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06094296
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06094296 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 196 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.